BioSpace News Archive

Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, announced that it has granted inducement stock options to purchase an aggregate of 89,550 shares of its common stock to 12 new employees.

Marvel Biosciences Inc. (TSXV: MRVL) (the “Company” or “Marvel”) highlights recent research indicating a link between non-alcoholic steatohepatitis (NASH) and Alzheimer’s Disease (AD), two programs its lead asset, MB-204 are targeting.

Today, the U.S. Food and Drug Administration approved Xenpozyme (Olipudase alfa) for intravenous infusion in pediatric and adult patients with Acid Sphingomyelinase Deficiency (ASMD), a rare genetic disease that causes premature death.

Zealand Pharma A/S announces the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.

Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced that the company will participate in two upcoming investor conferences.

Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that management will conduct fireside chats at the following healthcare conferences.

Foghorn® Therapeutics Inc. announced that Cigall Kadoch, Ph.D., a co-founder of the Company, has accepted her appointment as an Investigator for the Howard Hughes Medical Institute, effective on September 6, 2022.

Precision Optics Corporation, Inc. announced preliminary revenue for the fourth quarter and fiscal year end 2022, ended June 30, 2022 and provided an update on its process to list its shares on the Nasdaq Capital Market.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), today announced that it has obtained an award for up to $63.2 million from the Biomedical Advanced Research and Development Authority (BARDA).

NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in the H.C. Wainwright 24th Annual Global Investment Conference to take place in-person in New York and virtually September 12th-14th 2022.